Scinopharm Taiwan (TPE:1789) Moat Score: 0/10 (As of Jul. 08, 2026)


TPE:1789 Scinopharm Taiwan Ltd TPE:1789
75 GF Score
Price NT$20.80
GF Value NT$27.21
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Moat Score?

Scinopharm Taiwan has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Scinopharm Taiwan has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Scinopharm Taiwan might have No Moat - No discernible moat.

Scinopharm Taiwan  (TPE:1789) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Scinopharm Taiwan Moat Score Related Terms

TPE:1789
75GF Score
Scinopharm Taiwan Ltd TPE:1789
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$20.80 is trading 23.6% below its estimated GF Value™ of NT$27.21. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Moat Score: 0
  • GF Value™: NT$27.21 vs. price of NT$20.80 (23.6% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
75GF Score

Get the complete analysis for TPE:1789

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.80
Price
NT$27.21
GF Value